Swiftpharma SRL
12.3 FTESwiftpharma reported total assets of €4.90m at the end of the 2025 financial year (annual accounts filed with the NBB on 27 Apr 2026), with 12.3 full-time equivalents.
The score of Swiftpharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2023 → 2025: Equity +1302 % Total assets +335 % Headcount (avg FTE) +1130 %
Accounts of the company itself (not consolidated).
The full file covers 3 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Swiftpharma's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 27 Apr 2026
- Year ended 31 Dec 2024filed on 17 Jun 2025
- Year ended 31 Dec 2023filed on 25 Jul 2024
Swiftpharma's financial analysis
- Solvency17.0%sector median: 46.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Swiftpharma
Swiftpharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0781.598.284
- VAT number
- BE0781598284
- Peppol
- Registered · 0208:0781598284 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 04 Feb 2022
- Registered office
- 3600 Genk
- Size
- Small · 12.3 FTE
- Latest accounts
- 2025 · filed on 27 Apr 2026
- Activity
- Wholesale of pharmaceutical and medical goods (NACE 46460)
Swiftpharma (SRL) has been based in Genk since 2022, active in: wholesale of pharmaceutical and medical goods. For 2025, it reports a net loss of €1.75m and equity of 834,755 €; its revenue is not published. With 12.3 full-time equivalents, it is a small enterprise by headcount. Its solvency stands at 17.0%, below the median of its sector (46.0%).
Companies similar to Swiftpharma
Companies in the same business, of comparable size and area, outside its group.
- RevaTis Manufacture of pharmaceutical preparations Marche-en-Famenne · balance sheet €4.12m
- ExoXpert Manufacture of pharmaceutical preparations Liège · balance sheet €2.05m
- Xedev Other information service activities Zele · balance sheet €2.72m
- Boehringer Ingelheim Veterinary Medicine Belgium NV Research and experimental development on natural sciences and engineering Evergem · balance sheet €6.51m
- Sartorius Xpress Biologics Manufacture of basic pharmaceutical products Herstal · balance sheet €10.9m
- Etherna Immunotherapies Research and experimental development on natural sciences and engineering Niel · balance sheet €12.8m
- Bioxtract Research and experimental development on natural sciences and engineering Somme-Leuze · balance sheet €1.09m
- Unisensor Manufacture of basic pharmaceutical products Seraing · balance sheet €19.2m
Frequently asked questions about Swiftpharma
What is the revenue of Swiftpharma?
Swiftpharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Swiftpharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0781598284 for Swiftpharma, if the company is VAT-registered. Its company number (CBE) is 0781.598.284.
Where is the registered office of Swiftpharma?
According to the CBE register, the registered office of Swiftpharma is in 3600 Genk.
What is the equity of Swiftpharma?
At the close of the 2025 financial year, the equity of Swiftpharma amounts to 834,755 €, a solvency of 17.0% of total assets.
How many people work at Swiftpharma?
12.3 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Swiftpharma?
The register lists 3 active mandates at Swiftpharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Swiftpharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →